Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACET | US
0
0%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
24/04/2026
7.90
7.95
7.96
7.78
Adicet Bio Inc. a clinical stage biotechnology company discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting facilitate innate and adaptive anti-tumor immune response and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001 which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002 which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925 a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio Inc. is based in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
102.0%1 month
90.2%3 months
73.6%6 months
71.8%-
-
0.51
0.08
0.07
-1.21
2.14
0.82
-121.50M
650.97M
650.97M
-
-
-
-100.00
-57.91
9.15
5.34
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.73
Range1M
2.77
Range3M
2.99
Rel. volume
0.36
Price X volume
396.76K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals Inc | IRWD | Drug Manufacturers-Specialty & Generic | 3.93 | 627.77M | 3.69% | 55.00 | -199.01% |
| PAR Technology Corporation | PAR | Drug Manufacturers-Specialty & Generic | 13.71 | 497.45M | 2.16% | n/a | 65.19% |
| Elite Pharmaceuticals Inc | ELTP | Drug Manufacturers-Specialty & Generic | 0.3631 | 391.20M | 0.44% | 29.50 | 0.00% |
| Aquestive Therapeutics Inc | AQST | Drug Manufacturers-Specialty & Generic | 4.08 | 371.52M | 0.25% | n/a | -329.45% |
| Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 2.32 | 339.61M | 0.43% | n/a | 36.36% |
| Cipher Pharmaceuticals Inc | CPHRF | Drug Manufacturers-Specialty & Generic | 13.27 | 339.22M | -0.15% | 13.22 | 0.00% |
| Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 5.3 | 334.40M | -0.19% | n/a | 656.27% |
| Organogenesis Holdings Inc | ORGO | Drug Manufacturers-Specialty & Generic | 2.35 | 311.55M | 0.86% | n/a | 42.12% |
| Solid Biosciences Inc | SLDB | Drug Manufacturers-Specialty & Generic | 7.92 | 305.67M | -3.65% | n/a | 13.09% |
| Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 12.37 | 221.35M | -2.60% | n/a | 0.60% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.48 | 337.57M | 8.41% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.31 | 317.09M | 1.85% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.99 | 277.39M | -0.99% | 13.23 | 0.00% |
| CPI Card Group Inc | PMTS | Building Products & Equipment | 18.17 | 202.74M | 2.83% | 15.61 | -621.78% |
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 11.3 | 181.44M | 2.73% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 36.11 | 103.70M | 0.00% | 5.16 | 19.82% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.21 | 24.85 | Cheaper |
| Ent. to Revenue | 2.14 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 0.51 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 73.57 | 65.24 | Par |
| Debt to Equity | 0.08 | -1.88 | Expensive |
| Debt to Assets | 0.07 | 0.48 | Cheaper |
| Market Cap | 650.97M | 3.71B | Emerging |